#593 1984 · U.S. Congress (Rep. Henry Waxman and Sen. Orrin Hatch) · Pharmaceuticals / patent law
Congress ended a pharma industry stalemate by trading each side exactly what only the other side's cooperation could deliver
the problem
Brand-name and generic drugmakers were each blocked by a problem only the other industry's political support could fix
background
By the early 1980s, brand-name pharmaceutical companies and the generic drug industry were locked in a standoff neither side could break through Congress alone. Brand companies watched years of their patents' useful life quietly disappear while the FDA's own approval process dragged on, since a patent's fixed term started running the moment it was granted, regardless of how long regulatory review took to actually let the drug reach market.
Generic manufacturers, meanwhile, had just been dealt a serious blow: in 1984 the Federal Circuit ruled in Roche v. Bolar that even testing a patented drug to prepare a generic version — years before the patent expired, purely to gather the data the FDA would eventually require — counted as patent infringement. That ruling meant generics couldn't legally begin the FDA approval process until a patent had already expired, adding years of additional de facto exclusivity on top of whatever patent term remained.
what everyone would do
Let each side fight for its own preferred fix separately — brand companies lobbying for patent term extension alone, generic companies lobbying to overturn Roche v. Bolar and speed up approval alone — which is exactly the setup that had already produced years of stalemate, since neither industry had enough political weight on its own to pass a bill the other industry would actively lobby against.
what they saw
Brand and generic drugmakers weren't actually fighting over the same thing — brand companies wanted their patent term protected from erosion by FDA review delays, and generic companies wanted a legal path to prepare and file for approval before a patent expired. Because those were two separate, severable asks, they could be put in the same bill as a trade: give each industry exactly what only the other's cooperation could deliver, and neither industry's lobby had a reason left to oppose the whole package.
the move
Representative Henry Waxman and Senator Orrin Hatch negotiated a single bill, the Drug Price Competition and Patent Term Restoration Act of 1984, that traded each industry exactly what only the other side's cooperation could deliver: brand-name companies got patent term restoration to recoup years lost to regulatory delay, while generic manufacturers got a statutory "safe harbor" overturning Roche v. Bolar and an expedited abbreviated approval pathway (ANDA) that let them rely on the brand drug's existing safety data instead of repeating full clinical trials.
why it works
Patent term restoration and the ANDA safe-harbor generic pathway were bundled into one bill instead of run as two separate, competing legislative fights, so a vote for the bill meant accepting both halves of the trade rather than picking a side. Roche v. Bolar had just handed generics a real, immediate grievance — the Federal Circuit had explicitly ruled pre-expiration testing infringing — and FDA review delays had handed brand companies an equally real, immediate grievance, so each side arrived at the table with a concrete, current loss the other side's concession could actually fix, not an abstract ask either side could keep stalling indefinitely.
the payoff
Both halves of the deal passed together on September 24, 1984, because each industry's lobby stood to gain more from the trade than from continuing to block the other side's ask indefinitely. Brand companies got their lost patent years restored; generic companies got a legal, far faster path to market the moment a patent expired — reshaping the economics of both industries for decades.
where it breaks
It only works when the two sides' asks are genuinely severable and roughly balanced in value — if one industry's concession is worth far more than what it receives in return, that industry has no reason to stop lobbying against the bill even once bundled. It also depends on both problems being ripe at the same political moment; Roche v. Bolar's 1984 ruling created exactly the urgency and leverage that made generics willing to trade, and a bargain struck earlier or later might not have found both sides equally motivated to deal.
what came after
The Hatch-Waxman framework remains the backbone of U.S. pharmaceutical patent and generic-approval law four decades later, and its "grand bargain" structure — pairing two industries' separate, unrelated asks into one bill neither could pass alone — became a template lawmakers have reached for since whenever two opposed industries are each blocking the other's preferred legislative fix.
references
- [1]The Hatch-Waxman Act: A PrimerCongressional Research Service (via EveryCRSReport.com), 2016everycrsreport.com
- [2]Understanding Bolar and Bolar-Like Exceptions in U.S. and Abroad – Part 1The National Law Review, 2023natlawreview.com